318 related articles for article (PubMed ID: 24637946)
21. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.
Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR
J Virol; 2017 May; 91(9):. PubMed ID: 28202762
[TBL] [Abstract][Full Text] [Related]
22. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
23. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.
Gómez CE; Perdiguero B; Falqui M; Marín MQ; Bécares M; Sorzano CÓS; García-Arriaza J; Esteban M; Guerra S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115866
[TBL] [Abstract][Full Text] [Related]
26. Prospects for a Globally Effective HIV-1 Vaccine.
Excler JL; Robb ML; Kim JH
Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S307-18. PubMed ID: 26590431
[TBL] [Abstract][Full Text] [Related]
27. Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.
Wen Y; Trinh HV; Linton CE; Tani C; Norais N; Martinez-Guzman D; Ramesh P; Sun Y; Situ F; Karaca-Griffin S; Hamlin C; Onkar S; Tian S; Hilt S; Malyala P; Lodaya R; Li N; Otten G; Palladino G; Friedrich K; Aggarwal Y; LaBranche C; Duffy R; Shen X; Tomaras GD; Montefiori DC; Fulp W; Gottardo R; Burke B; Ulmer JB; Zolla-Pazner S; Liao HX; Haynes BF; Michael NL; Kim JH; Rao M; O'Connell RJ; Carfi A; Barnett SW
PLoS One; 2018; 13(4):e0194266. PubMed ID: 29698406
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
[TBL] [Abstract][Full Text] [Related]
29. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
O'Connell RJ; Kim JH; Excler JL
Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
[TBL] [Abstract][Full Text] [Related]
30. Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost.
Joachim A; Ahmed MIM; Pollakis G; Rogers L; Hoffmann VS; Munseri P; Aboud S; Lyamuya EF; Bakari M; Robb ML; Wahren B; Sandstrom E; Nilsson C; Biberfeld G; Geldmacher C; Held K
Front Immunol; 2020; 11():719. PubMed ID: 32411138
[TBL] [Abstract][Full Text] [Related]
31. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
Belshe RB; Gorse GJ; Mulligan MJ; Evans TG; Keefer MC; Excler JL; Duliege AM; Tartaglia J; Cox WI; McNamara J; Hwang KL; Bradney A; Montefiori D; Weinhold KJ
AIDS; 1998 Dec; 12(18):2407-15. PubMed ID: 9875578
[TBL] [Abstract][Full Text] [Related]
32. Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
Khattar SK; Samal S; LaBranche CC; Montefiori DC; Collins PL; Samal SK
PLoS One; 2013; 8(10):e78521. PubMed ID: 24098600
[TBL] [Abstract][Full Text] [Related]
33. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.
Spearman P; Lally MA; Elizaga M; Montefiori D; Tomaras GD; McElrath MJ; Hural J; De Rosa SC; Sato A; Huang Y; Frey SE; Sato P; Donnelly J; Barnett S; Corey LJ;
J Infect Dis; 2011 Apr; 203(8):1165-73. PubMed ID: 21451004
[TBL] [Abstract][Full Text] [Related]
34. Critical issues in mucosal immunity for HIV-1 vaccine development.
Haynes BF; Shattock RJ
J Allergy Clin Immunol; 2008 Jul; 122(1):3-9; quiz 10-1. PubMed ID: 18468671
[TBL] [Abstract][Full Text] [Related]
35. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
[TBL] [Abstract][Full Text] [Related]
36. DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial.
Rouphael NG; Morgan C; Li SS; Jensen R; Sanchez B; Karuna S; Swann E; Sobieszczyk ME; Frank I; Wilson GJ; Tieu HV; Maenza J; Norwood A; Kobie J; Sinangil F; Pantaleo G; Ding S; McElrath MJ; De Rosa SC; Montefiori DC; Ferrari G; Tomaras GD; Keefer MC;
J Clin Invest; 2019 Nov; 129(11):4769-4785. PubMed ID: 31566579
[TBL] [Abstract][Full Text] [Related]
37. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
[TBL] [Abstract][Full Text] [Related]
38. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
[TBL] [Abstract][Full Text] [Related]
39. Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.
Page M; Stebbings R; Berry N; Hull R; Ferguson D; Davis L; Duffy L; Elsley W; Hall J; Ham C; Hassall M; Li B; Mee ET; Quartey-Papafio R; Rose NJ; Mathy N; Voss G; Stott EJ; Almond N
Retrovirology; 2012 Jul; 9():56. PubMed ID: 22799593
[TBL] [Abstract][Full Text] [Related]
40. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.
Leroux-Roels I; Koutsoukos M; Clement F; Steyaert S; Janssens M; Bourguignon P; Cohen K; Altfeld M; Vandepapelière P; Pedneault L; McNally L; Leroux-Roels G; Voss G
Vaccine; 2010 Oct; 28(43):7016-24. PubMed ID: 20728522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
